The association said the new guidance is based on anecdotal reports of patients who take these drugs experiencing regurgitation and aspiration while undergoing anesthesia. There is “a lack of scientific data on how GLP-1 receptor agonists affect patients having surgery and interact with anesthesia,” ASA President Michael Champeau, MD, said in a news release.
GLP-1 drugs, or glucagon-like peptide 1 agonists, are a class of medications that suppress appetite. As of June 29, the FDA has approved 10 GLP-1 therapies:
- Adlyxin (lixisenatide)
- Bydureon BCise (exenatide extended release)
- Byetta (exenatide)
- Mounjaro (tirzepatide)
- Ozempic (semaglutide)
- Rybelsus (semaglutide)
- Saxenda (liraglutide)
- Trulicity (dulaglutide)
- Victoza (liraglutide)
- Wegovy (semaglutide)
All are approved to treat Type 2 diabetes except for Saxenda and Wegovy, which are approved for weight loss.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
